Drug-induced liver disease

Current Opinion in Gastroenterology

Volumn 13, Issue 3, 1997, Pages 199-205

  Lee, Alice U ^a   Farrell, Geoffrey C ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYPROTERONE ACETATE; DACARBAZINE; FLUTAMIDE; TACRINE; TAMOXIFEN; TEGAFUR; TERBINAFINE; TODRALAZINE; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; DRUG ABUSE; HERBAL MEDICINE; HUMAN; LIVER FAILURE; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; PATHOGENESIS;

EID: 0030925605     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199705000-00005     Document Type: Article

References (66)

1. Farrell GC: Drug-Induced Liver Disease. Edinburgh: Churchill Livingstone: 1994.
2. Cameron RG, Feuer G, de la Iglesia FA, eds.: Drug-induced hepatotoxicity. In Handbook of Experimental Pharmacology, vol 121. Berlin: Springer: 1996.
3. Lee WM: Drug-induced hepatotoxicity. N Engl J Med 1995, 333:1118-1127.
4. Farrell GC, Weltman M: Drug-induced liver disease. In Current •• Hepatology, vol 16. Edited by Gitnick G. St. Louis: Mosby: 1996:143-208. This comprehensive review outlines the recent developments in drug-induced liver disease and covers a broad range of topics, from the mechanisms of toxicity to interesting and relevant clinical reports.
5. Weltman M, Samarasinghe D, George J, Farrell GC: Drug-induced liver disease. In Current Hepatology, vol 15. Edited by Gitnick G. St. Louis: Mosby; 1995:145-195.
6. Samarasinghe D, George J, Farrell GC: Drug-induced liver disease. In Current Hepatology, vol 14. Edited by Gitnick G. St. Louis: Mosby; 1994:117-167.
7. Davies EG, Pollack I, Steel HM: Chinese herbs for eczema [letter]. Lancet 1991, 336:177.
8. Kane JA, Kane SP, Jain S: Hepatitis induced by traditional Chinese herbs: possible toxic components. Gut 1995, 36:146-147.
9. Perharic-Walton L, Murray ID: Toxicities of traditional Chinese herbal remedies [letter]. Lancet 1992, 340:674.
10. Smith BC, Desmond PV: Acute hepatitis induced by the ingestion of the herbal medication chaparral. Aust N Z J Med 1993, 23:526.
11. Katz M, Saibil F: Herbal hepatitis. Subacute hepatic necrosis secondary to chaparral leaf. J Clin Gastroenterol 1990, 12:203-206.
12. Alderman S, Goldfarb S, Malone DG: Cholestatic hepatitis after ingestion of chaparral leaf: confirmation by endoscopic retrograde cholangio-pancreatography and liver biopsy. J Clin Gastroenterol 1994, 19:242-247.
13. Gordon DW, Rosenthal G, Hart J, Sirota R, Baker AL: Chaparral ingestion: the broadening spectrum of liver injury caused by herbal medications. JAMA 1995, 273:489-490.
14. Batchelor WB, Heathcote J, Wanless IR: Chaparral-induced hepatic injury. Am J Gastroenterol 1995, 90:831-833.
15. Woolf GM, Petrovic LM, Rojter SE, Wainwright S, Villamil FG, Katkov WN, Michieletti P, Wanless IR, Stermitz FR, Beck JJ, et al. Acute hepatitis associated with the Chinese herbal product Jin Bu Huan. Ann Intern Med 1994, 121:729-735.
16. Dao T, Peytier A, Galateau F. Valla A: Chronic hepatitis due to germander. Gastroenterol Clin Biol 1993, 17:614-615.
17. Larrey D, Vial T, Pauwels A, Castot A, Biour M, David M, Michel H: Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity. Ann Intern Med 1992, 117:129-132.
18. Laliberte L, Villeneuve JP: Hepatitis after use of germander, a herbal remedy. Can Med Assoc J 1996, 154:1689-1692.
19. Mattei A, Rucay P, Samuel D, Feray C, Michel R, Bismuth H: Liver transplantation for acute liver failure after herbal medicine (Teucrium polium) administration [letter]. J Hepatol 1995, 22:597.
20. Perron AD, Patterson JA, Yanofsky NN: Kombucha "mushroom" hepatotoxicity [letter]. Ann Emerg Med 1995, 26:660-661.
21. Dykhuizen RS, Brunt PW, Atkinson P, Simpson JG, Smith CC: Ecstasy-induced hepatitis mimicking viral hepatitis. Gut 1995, 36:939-941.
22. Fidler H, Dillhon A, Gertner D, Burroughs A: Chronic ecstasy (3,4-methylenedioxymetamphetamine) abuse: a recurrent and unpredictable cause of severe acute hepatitis. J Hepatol 1996, 25:563-566.
23. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW: Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994, 271:992-998.
24. Woolf TF, Pool WF, Kukan M, Bezek S, Kunze K, Trager WF: Characterisation of tacrine metabolism and bioactivation using heterologous expression systems and inhibitions studies: evidence for CYP 1A2 involvement [abstract], ISSX Proceedings, 1993.
25. Fontana RJ, Turgeon TF, Woolf TF, Knapp MJ, Foster NL, Watkins PB: The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity. Hepatology 1996, 23:1430-1435.
26. Berson A, Renalut S, Letteron P, Robin MA, Fromenty B, Fau D, Le Bot MA, Riche C, Durand-Schneider AM, Feldmann G, et al.: Uncoupling of rat and human mitochondria: a possible explanation for tacrine-induced liver dysfunction. Gastroenterology 1996, 110:1878-1890.
27. Parys BT, Hamid S, Thomson RGN: Severe hepatocellular dysfunction following cyproterone acetate therapy. Br J Urol 1991, 67:312-313.
28. Roila F, Crino L, Carloni G, Natalina G: Cyproterone acetate: hepatotoxicity and prostate cancer treatment [letter]. Ann Oncol 1993, 4:701.
29. Pinganaud G, Chaslerie A, Bourdel Marchasson I, Decamps A, Manciet G, Emeriau JP: Cyproterone-induced hepatotoxicity [letter]. Ann Pharmacother 1995, 29:634.
30. Gomez J-L, Duport A, Cusan L, Tremblay M, Suburu R, Lemay M, Labrie F: Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. Am J Med 1992, 92:465-470.
31. Wysowski DK, Fourcroy JL: Flutamide hepatotoxicity. J Urol 1996, 155:209-212.
32. Rosenthal SA, Linstadt DE, Leibenhaut MH, Andras EJ, Brooks CP, Stickney DR, Chang GC, Wolkov HB, Gilbert RM: Flutamide-associated liver toxicity during treatment with total androgen suppression and radiation therapy for prostate cancer. Radiology 1996, 199:451-455.
33. Hart W, Stricker BH: Flutamide and hepatitis [letter]. Ann Intern Med 1989, 110:943-944.
34. Fau D, Eugene D, Berson A, Letleron P, Fromenty B, Fisch C, Pessayre D: Toxicity of antiandrogen flutamide in isolated rat hepatocyte. J Pharmacol Exp Ther 1994, 269:954-962.
35. Lazaros GA, Papatheodoridis GV, Delldetsima JK, Tassopoulos NC: Terbinafine-induced cholestatic liver disease. J Hepatol 1996, 24:753-756.
36. Lowe G, Green C, Jennings P: Hepatitis associated with terbinafine treatment. BMJ 1993, 23;306:248.
37. van't Wout JW, Herrmann WA, De Vries RA, Stricker BHC: Terbinafine-associated hepatic injury. J Hepatology 1994, 21:115-117.
38. Bachs L, Parés A, Elena M, Piera C, Rodés J: Effects of long term rifampicin administration in primary biliary cirrhosis. Gastroenterology 1992, 102:2077-2080.
39. Singh J, Arora A, Garg PK, Thakur VS, Pande JN, Tandon RK: Antituberculosis treatment-induced hepatotoxicity: role of predictive factors. Postgrad Med J 1995, 71:359-362.
40. Van Den Brande P, Van Steenbergen W, Vervoort G, Demedts M: Aging and heptotoxicity of isoniazid and rifampicin in pulmonary tuberculosis. Am J Resp Crit Care Med 1995, 152:1705-1708.
41. Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR: Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975, 69:289-302.
42. Maddrey WC: Isoniazid-induced liver disease. Semin Liver Dis 1981, 1:129-133.
43. Ozick LA, Jacob L, Comer GM, Lee TP, Ben-Zvi J, Donelson SS, Felton CP: Hepatotoxicity from isoniazid and rifampicin in inner-city AIDS patients. Am J Gastroenterol 1995, 90:1978-1980.
44. Askgaard D, Wilcke T, Dossing M: Hepatotoxicity caused by the combined action of isoniazid and rifampicin. Thorax 1995, 50:213-214.
45. Corbella X, Vadillo M, Cabellos C, Fernandez-Viladrich P, Rufi G: Hypersensitivity hepatitis due to pyrazinamide. Scand J Infect Dis 1995, 27:93-94.
46. Thompson NP, Caplin ME, Hamilton MI, Gillespie SH, Clarke SW, •• Burroughs AK, McIntyre N: Antituberculosis medication and the liver: dangers and recommendations in management. Eur Respir J 1995, 8:1384-1388. Literature review of antituberculous drug-associated hepatotoxicity and current recommendations on the monitoring of liver function during therapy. These recommendations include clear protocols for action to be taken in case of adverse events.
47. Bartoli E, Solinas A, Chiandussi L: Acute hepatitis with bridging necrosis due to hydralazine intake. Arch Intern Med 1980, 139:698-699.
48. Jon GP, Peschle C: Hydralazine disease associated with transient granulomas in the liver. Gastroenterology 1973, 64:1163-1167.
49. Itoh S, Tsukada Y, Itoh Y: Hydralazine-induced hepatitis. Hepatogastroenterology 1981, 28:13-16.
50. Itoh S, Yamada Y, Ichinoe A, Tsukada Y: Hydralazine-induced liver injury. Dig Dis Sci 1980, 25:884-887.
51. Tameda Y, Hamada M, Takase K, Nakano T, Kosaka Y: Fulminant hepatic failure caused by ecarazine hydrochloride (a hydralazine derivative). Hepatology 1996, 23:465-470.
52. Loomus GN, Aneja P, Bota RA: A case of peliosis hepatis in association with tamoxifen therapy. Am J Clin Pathol 1983, 80:881-883.
53. Blackburn AM, Amiel SA, Millis RR, Rubens RD: Tamoxifen and liver damage. BMJ 1984, 289:288.
54. Ludwig J, ed: In Practical Liver Biopsy Interpretation-Diagnostic Algorithms. Chicago: ASCP Press; 1992:65.
55. Ching CK, Smith PG, Long RG: Tamoxifen associated hepatocellular damage and agranulocytosis. Lancet 1992, 339:40.
56. Pinto HC, Baptists A, Camilo ME, de Costa EB, Valente A, de Moura MC: Tamoxifen-associated steatohepatitis-report of three cases. J Hepatol 1995, 23:95-97.
57. Van Hoof M, Rahier J, Horsmans Y: Tamoxifen-induced steatohepatitis. Ann Intern Med 1996, 124;9:855-856.
58. Carthew P, Martin EA, White IN, De Matteis F, Edwards RE, Dorman BM, Heydon RT, Smith LL: Tamoxifen induces short-term cumulative DNA damage and liver tumors in rats: promotion by phenobarbital. Cancer Res 1995, 55:544-547.
59. Baba M, Shima T, Tanaka T, Nakayabu M, Hasegawa H, Suzuki S, Kusano I: A case of allergic liver injury induced by tegafur. J Gastroenterol 1994, 29:88-92.
60. Seki S, Mizoguchi Y, Saito S, Shiomi S, Sakagami Y, Sokaguchi H, Kuroki T, Harihara S, Kobayashi K, Monna T, et al.: A clinicopathological study of 11 patients with drug-induced acute hepatic failure. Jpn J Gastroenterol 1986, 83:2545-2549.
61. Abe Y, Ueda K, Ashida H: A case of drug-induced liver injury by tegafur. Acta Hepatol Jpn 1990, 31(suppl 2):85.
62. Maruyama S, Hirayama C, Abe J, Tanaka J, Matsui K: Chronic active hepatitis and liver cirrhosis in association with combined tamoxifen/tegafur adjuvant therapy. Dig Dis Sci 1995, 40:2602-2607.
63. R containing tegafur and uracil. Dig Dis Sci 1995, 40:2434-2437.
64. DeLeve LD: Dacarbazine toxicity in murine liver cells: a model of hepatic endothelial injury and glutathione defense. J Pharmacol Exp Ther 1994, 268:1261-1270.
65. DeLeve LD, Wang X, Kuhlenkamp JF, Kaplowitz N: Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease. Hepatology 1996, 23:589-599.
66. DeLeve LD, Wang X, Huybrechts MM: Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology 1996, 24:830-837.